GSK Negotiates Potential Acquisition of Nuvalent for Over $9 Billion
GSK is reportedly in discussions to acquire cancer biotech Nuvalent, a deal that could surpass $9 billion and mark one of the largest transactions for the UK drugmaker amid rising biotech M&A activity this year.
Editorial Staff
1 min read
Updated about 19 hours ago
GlaxoSmithKline (GSK) is currently in talks to purchase Nuvalent, a biotech firm specializing in cancer treatments, for a sum exceeding $9 billion.
If finalized, this acquisition would be among the largest in GSK's history, reflecting a significant move in the competitive landscape of biotech mergers and acquisitions this year.
The discussions come at a time when the biotech sector is experiencing heightened M&A activity, indicating a potential shift in investment strategies within the pharmaceutical industry.